INTRODUCTION
The ability of urine to lyse a crude fibrin clot was described by Sahli (1) at the turn of the century. Subsequent studies by Sobel, Mohler, Jones, Dowdy, and Guest (2), Williams (3) , and Astrup and Sterndorff (4) demonstrated that this property was due to the presence of a plasminogen activator, named urokinase by the former group of investigators (2) . Urokinase has been prepared in highly purified form (5, 6) , and one group (5) has reported its crystallization. While it is inferred that plasminogen activators appearing in body fluids originate from tissue sources, the original site of urokinase derivation is uncertain.
Since urine from the bladder and from the renal pelvis contains identical urokinase concentrations (7) , it is apparent that urokinase is derived either by clearance of plasma activator or directly or indirectly by renal formation; however, direct evidence to support any one of these suppositions is lacking. While limited correlation between plasma fibrinolytic activity and urokinase excretion has been suggested (8) , recent reports (9, 10) indicate that the kidney may be the site of urokinase production, and that urokinase excretion into the
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In the present studies, the effect of a specific human urokinase neutralizing antiserum on the biochemical activities of various human, animal, and other plasminogen activators has been determined. The results demonstrate (a) that human urokinase is immunologically distinct from both plasma plasminogen activator and human tissue activator prepared from adrenal glands, (b) that human renal tissue is capable of urokinase synthesis, but (c) that urokinase cannot be detected in the general circulation or renal venous blood of man.
METHODS
Assay of plasminogen activators. Urokinase activity was expressed in Committee on Thrombolytic Agents (CTA) units (11) . The activity of other plasminogen activators, i.e. staphylokinase, tissue activators, and activators in tissue culture supernates were expressed in equivalent units (11) as assayed by caseinolytic assay.
Fibrinogen (bovine),' 60%o clottable by thrombin, was used for the preparation of fibrin plates. Bovine fibrinogen which was 98%o clottable2 by thrombin was used as substrate for "2I iodination.
Bovine thrombin 3 was dissolved in saline at a concentration of 100 U/ml and frozen at -200 in 1-ml aliquots until use. Human plasminogen was prepared by the method of Kline and Fishman (12) and freeze dried. This material was assayed at 11 Remmert and Cohen casein U/mg of protein when assayed in comparison with a plasmin standard supplied by Michigan State Department of Health and was dissolved in distilled water immediately before use.
Human plasmin was prepared by activation of plasminogen with streptokinase and rendered activator free (13) .
Epsilon aminocaproic acid 1 solutions were prepared from crystalline material.
Streptokinase was supplied as Varidase. 4 Staphylokinase5 was used in the form of partially purified material which gave an activity of 154 CTA U/mg.
The plasma used was pooled outdated banked plasma stored frozen in small aliquots until use.
Urine was collected fresh and dialyzed in 10-ml aliquots 1 Nutritional Biochemicals Corporation, Cleveland, Ohio. 2 Kindly supplied by Dr. Grondahl, Karolinska Institute, Stockholm, Sweden. 3 Parke, Davis & Co., Detroit, Mich. 4Lederle Laboratories, Pearl River, N. Y. 5 Kindly supplied by Dr. C. Lack, Stanmore Hospital, Stanmore, England.
twice against 1 liter of 0.01 M P04 buffer, pH 7.6 (2.68 g of Na2HPO4, 7 H20 made up to 1 liter after adjustment of pH) for 18 hr to remove material which gave high spectrophotometric blank values at 280 mu and to adjust pH to obviate uropepsin activity. Alpha casein8 was also used (now available commercially from Worthington Biochemicals, Freehold, N. J.).
Urokinase 6 which assayed at 30,000 CTA U/mg of protein was used for immunization. It was albumin free and lyophilized from 0.1 M P04, 0.1 M NaCl solution. The material used in assays was a sterile heat-treated (60°C for 10 hr) preparation with albumin stabilizer, which contained 35,000 CTA U/mg of protein, before the addition of albumin.
Porcine tissue activator contained 15,000 CTA U/mg of protein.
Pig kidney tissue culture concentrate 8 was assayed at 1000 CTA U/mg of protein.
Cytokinase 9 was used in the form of a concentrated solution prepared from serum-free monkey kidney tissue culture supernatant and assayed at 750 CTA U/mg of protein.
Tissue culture supernates were obtained from monolayer RK-13 (rabbit embryo kidney), Hep (carcinoma of larynx), and Hela (carcinoma of cervix) grown from 3 to 5 days on Eagle's growth media containing 2% calf serum. Monkey kidney (MK) tissue culture activator was obtained from supernate of cultures grown on lactalbumin hydrolysate, serum-free media.
Adult human kidney tissue cultures were grown in Eagle's media with 2% horse serum and supernates collected after 5 days growth while the cells were seen to be viable. Material was frozen at -20°C until use. 10 Crude human milk activator was prepared by centrifuging fresh human milk at 15,000 g at 4°C for 20 min and utilizing the supernatant.
Human adrenal tissue activator was prepared by a modification of the methods of Bachmann, Fletcher, Alkjaersig, and Sherry (14, 15) . Fresh adrenal glands were collected and stored at -20°C. The frozen adrenals were minced and extracted with 5 M urea at pH 4.0 for 15 min at 4°C, and all subsequent purification steps were performed at this temperature. The urea solution was brought to 25%o ammonium sulfate concentration by the addition of salt; the solution was not neutralized. The resulting precipitate was discarded, and the supernatant was brought to 50% ammonium sulfate saturation. After centrifugation the precipitate was dissolved in 5M urea at pH 4.0, refractionated at 33% ammonium sulfate saturation, and the precipitate dissolved in 0.05 M acetic acid. The solution was dialyzed against 0.01 M acetic acid until the resistance exceeded 1000 ohms at room temperature.
The activator was precipitated by raising the pH to 6.5 with sodium-hydroxide for 15 min and redissolving in 0.05 M acetic acid; 1 ml of the solution contained 160 CTA U of activator activity.
Urokinase antiserum was produced by injecting the foot pads of Hartley strain guinea pigs with 0.4 mg of the urokinase preparation (in complete Freund's adjuvant) per animal. A booster injection with the same antigen preparation was given after 6 wk and blood collected 2 wk later. Serum was harvested after spontaneous clotting at 370C for 30 min.
Control guinea pig serum was obtained from the clotted whole blood (370C for 30 min) of nonimmunized Hartley strain guinea pigs.
Plasminogen activator activity in vitro was determined by the fibrin plate method (16) as modified by Alkjaersig, Fletcher, and Sherry (17) , by the plasma clot lysis method (18) , and by the euglobulin clot lysis method (19) with the results expressed in fibrinolytic units (20) . In certain experiments activator material and antisera were added to the dissolved euglobulin precipitate after its isolation. Epsilon aminocaproic acid (EACA) fibrin plates and antisera and control sera fibrin plates were prepared containing 0.01 M EACA or 0.1% serum, respectively.
Tissue In each instance in which activator activity was studied, a control experiment was done in the presence of 0.01 M EACA; the latter inhibited euglobulin or 1251I clot lysis from 86 to 100%, which confirmed that activator activity rather than nonspecific proteolysis or plasmin action was being assayed.
Esterase assays with acetyl-l-lysine methyl ester as substrate were done as previously described (22) .
Renin assays" were performed on plasma processed by the method of Helmer and Judson (23) , and nephrectomized, pentolinium-treated rats were used for assays (24 
RESULTS
Inhibitory effect of urokinase antisera on human urokinase activity. Fig. 1 demonstrates the inhibitory effect of urokinase antisera on plasminogen activation by purified human urokinase. Human urokinase (5 CTA U/ml of final concentration) and serially diluted antiserum were mixed and urokinase activity assayed by the fibrin plate method. Control serum in a dilution of 1: 10 completely inhibited urokinase activity, but a dilution of 1: 100 produced only minimal inhibition. By contrast, unboosted antiserum produced virtually complete inhibition in a dilution of 1: 600, and boosted antiserum produced complete inhibition at a 1: 1200 dilution. Thereafter a progressive lessening of inhibition occurred with further dilution of both antisera through 1: 2400. Boosted antiserum was employed in all subsequent experiments. Fig. 2 illustrates the action of urokinase antiserum in a plasma clot lysis assay system. Increasing concentrations of urokinase were added to plasma aliquots containing a constant concentra- tion of either antiserum, control serum, or saline. The mixture was immediately clotted with thrombin and the clot lysis time determined. The reciprocal of the lysis time is plotted against urokinase concentrations. The intercept of the plot for inhibition by urokinase antisera with the abscissa indicates that this batch of antiserum (AUKB4) neutralized approximately 50,000 CTA U of urokinase per ml, a finding confirmed by other experiments in which the 1251 plasma clot lysis assay was used.
Urokinase antiserum produced comparable inhibitory effects on purified urokinase and native human urokinase in urine, and these data are shown in Fig. 3 UROKINASE CONCENTRATION (CTA U/ml) FIGURE 2 Specific inhibition of urokinase by urokinase antisera shown with whole plasma clot lysis method. Urokinase (200-2000 CTA U/ml) was added to bank plasma, the mixture clotted immediately with thrombin, and clot lysis determined (expressed as 100 lysis time on the ordinate). Urokinase concentration is shown on the abscissa. 0----, urokinase in buffered saline, pH 7. urine specimens performed in the absence and presence of antiserum. They superimpose perfectly on the purified urokinase reference lines and demonstrate that the antiserum displayed an identical neutralizing titer against both native urokinase in human urine and purified urokinase. Higher concentrations of antiserum produced complete inhibition of urokinase activity in urine.
When similar experiments were performed with the acetyl-1-lysine methyl (ALMe) esterase assay rather than the caseinolytic assay, inhibition of urokinase by its antiserum was not demonstrable.
The kinetics of urokinase inhibition by antiserum was studied with the casein assay to quantify the velocity of plasminogen activation. The ordinate of Fig. 4 shows 1/velocity (1/OD, casein proteolysis) and the abscissa 1/substrate (1/plasminogen concentration). The Lineweaver-Burk plot demonstrates inhibition of the competitive type, a common pattern observed when antibodies inhibit the biochemical actions of enzymes.
Specificity of urokinase antiserum. The influence of urokinase antiserum on a variety of plasminogen activators and animal urines is shown in Fig. 5 and in Table I . Fig. 5 demonstrates that the antiserum failed to specifically neutralize either streptokinase (15 U/ml) when combined with a trace of human plasmin as a proactivator source, as shown by solid lines, or porcine tissue activator, shown by dashed lines, in a fibrin plate assay system. Significant differences between assay values when these activators were treated with control serum (open symbols) or urokinase antiserum (closed symbols) were not detected. The antiserum also failed to inhibit the activity of another plasminogen activator of bacterial origin, staphylokinase, when tested by the euglobulin clot lysis method.
Fig . 6 illustrates the assay principle used in determining the per cent of inhibition by urokinase antiserum against the plasminogen activators listed in Table I . The casein assay method was used. Since assay mixtures containing urokinase and control serum and those containing urokinase and antiserum each yield linear increases of OD as a function of urokinase concentration, 100 %7 inhibition by antiserum was defined, at any activity level, as the difference between these readings. For the experiment shown in Fig. 6 , serial dilutions of 0.5, 1.0, and 1.5 ml of dialyzed baboon urine were assayed in the presence of 0.02 % control serum and 0.02% antiserum. The values with control serum are plotted on the upper reference assay line and show a virtual linear increase in activity with urine volume. Addition of antiserum also produced a linear reduction in baboon urine assay values, but this was proportionately less than that with purified human urokinase; the The data indicate that antiserum to human urokinase has a negligible effect against the urokinase, tissue activator, and tissue culture supernates from nonprimate sources, i.e., dog, pig, rabbit, and guinea pig. Per cent of inhibition varied from 0-4 %o. In contrast antiserum has a significant effect against activators from primate urinary tract sources. The per cent of inhibition against rhesus urine, rhesus kidney tissue culture supernate, and cytokinase (partially purified rhesus kidney culture supernate) is in the 37-50 %o range. Baboon urine cross-reacted to a greater degree and showed 77 % inhibition.
Plasminogen activators from human sources treated with urokinase antiserum fall into two categories: first those which were completely inhibited, including all batches of purified human urokinase, human urine, and human kidney tissue culture supernate; and secondly, those with zero Table I (Bottom section). Marked inhibition is produced by urokinase antisera against urokinase-enriched, zero-time plasmas of subjects depicted in upper section. Euglobulin lysis assays were performed in the presence of 0.5-0.01%o urokinase antisera. Sufficient urokinase was added to zero-time subject plasmas to approximate fibrinolytic activity noted after the procedures performed above. Paired studies with control sera (not shown) gave minimal nonspecific inhibition ranging from 5-22% with 0.5% control serum. the procedure and activator concentration studied by the euglobulin clot lysis method. The redissolved euglobulin precipitates of these plasmas were divided into aliquots and treated respectively with serial dilutions of either urokinase antiserum or control serum. The mixtures were clotted with thrombin and the lysis time determined. The results shown in Fig. 8 (upper section) failed to demonstrate specific inhibition of plasma plasminogen activator when assayed in the presence of urokinase antiserum ranging from 0.5 %o to 0.01 %, final concentration.
The paired studies with serial dilution of control guinea pig serum gave virtually identical results with those depicted in Fig. 8 with a Five additional subjects, three normal and two patients with cirrhosis, were similarly studied with the 1251-labeled clot lysis assay. In this instance, antisera and control sera were added directly to subject plasma after the experimental procedures and to the zero-time plasma samples which had been enriched with urokinase. Because the experimental subjects exhibited variable enhancement of plasma plasminogen activator levels after stress, the results in Fig. 9 are expressed as per cent of inhibition produced by the sera compared to assays performed with saline and are displayed as the mean values for all five subjects. Though high concentration of antiserum produced apparently minor inhibitions of activity in the plasma samples drawn after stress, the differences between treatment with antiserum (line 2) and control serum (line 3) were not statistically significant (P > 0.1 ). In contrast, the effect of control serum (line 4) and antiserum (line 1) on urokinase-enriched plasma was markedly different. Control serum failed to produce significant inhibition in any concentration, whereas antiserum produced virtually complete inhibition in concentrations above 10-, and definite inhibition was noted in concentrations as low as 10-3-4.
Renal venous blood studies. The following studies were performed to determine whether urokinase could be detected in either renal venous or inferior vena cava plasma samples, particularly under conditions in which high levels of plasma plasminogen activator were present. Sample collection was performed by catheterization under fluoroscopic control or direct aspiration at surgery, and sampling was done simultaneously or with a very short interval required for catheter flushing. The six subjects studied were being investigated for suspected renal vascular hypertension or for cardiac abnormalities, and the clinical data and results of euglobulin clot lysis, 125I-labeled clot lysis, and plasma renin assays are shown in Table  II . All subjects except No. 3 had normal renal function by chemical and radiographic criteria. In subjects 2-5, no specific stimulus other than that of the investigational catheterization or surgery was used to enhance plasma plasminogen activator concentration. In subject 6, 100 mg of nicotinic acid was injected via catheter into the renal vein. In subject 1, contrast media was injected into the left renal vein before the collection of this final sample.
Subject 1 showed comparable levels of plasminogen activator in the right renal and inferior vena cava plasma samples. The left renal plasma was assayed at considerably higher levels in the sample taken after contrast media injection, probably because of the vasoactive effect of this agent in high concentration. The remainder of the subjects showed comparable titers of plasma plasminogen activator in renal and inferior vena cava (IVC) plasma. Subject 3 produced fibrinolytic assay values of a similar magnitude to the other subjects in spite of impaired renal function. Renin Human Plasminogen Activators and Urokinase eU These data show that in both assay systems, control serum produced a small degree of inhibition in renal and IVC plasma. Treatment with urokinase antiserum as seen in Table III is highly inhibitory against urokinase-enriched plasma. By contrast, plasma plasminogen activator in either renal venous or IVC plasma was not specifically inhibited by urokinase antiserum.
DISCUSSION
Plasminogen activators are widely distributed in various organs and body fluids; they are named with reference to the site of occurrence. Thus the term tissue activator designates activators extracted from specific tissues; plasma and milk activators are those activators present in plasma and milk, respectively, and urokinase, the activator present in urine. Except in the case of human urokinase which has been highly purified (5, 6) and porcine heart activator which has been substantially purified (15) , little is known of the properties, precise origins, and interrelationships of the individual activators. Of particular significance are the interrelationships and identities of tissue activators, plasma activator, and urokinase.
The finding of concomitant increases in the plasma fibrinolytic activity and urokinase excre- (31) using vasoactive drugs to produce transient enhancement of plasma activator levels failed to demonstrate increased urokinase excretion. The latter author reported that plasma activator was not additive in neutralizing urokinase inhibitors in plasma. Urokinase has also been reported as possessing greater thermostability than plasma activator at low pH (32) . The relationship of urokinase and tissue activator is similarly undefined except for reports that they have similar thermostability (33) . Urokinase and porcine tissue activator have been reported as having different ratios of affinity to plasminogen in solution (as in plasma) vs. plasminogen in the gel phase (as in a fibrin clot) (15) .
Recent evidence, indicating (a) that activator concentration is higher in renal venous than arterial blood in both man and animals (34) and (b) that plasma activator concentration fell during mercuric chloride intoxication (9, 25) and clamping of the renal vessels (10) suggests that the kidney may serve as a significant source of plasma activator. A clearing function for plasma activator by the liver is suggested by studies which detected increased levels of this activator in animals in which the hepatic vessels had been clamped (10) , in humans with cirrhosis (35) , and in animals in which liver transplantation was being performed (36) . Bachmann has shown clearance of both plasma activator and exogenously injected urokinase into bile by the liver (37) . However, definiHuman Plasminogen Activators and Urokinase tive identification of urokinase in systemic blood or renal venous plasma has not been accomplished, and the evidence for its presence in these fluids has been inferential.
In 1965 Lesuk, Terminiello, and Traver (5) described a method for the preparation of crystalline human urokinase; this crystalline material fulfilled several biophysical criteria for homogeneity and had a molecular weight of 54,000. Subsequently White, Barlow, and Mozen (6) , who, by alternative methods prepared urokinase of comparable specific activity to that of Lesuk et al., described preparation inhomogeneity and the presence of at least three molecular species (S1, mol wt 31,500 and S2, mol wt 54,700, the main types). Type S, urokinase had a specific activity approximately twice that of S2, but antisera prepared against S, showed reaction of identity with S, material. However, recent studies by Lesuk, Terminiello, Traver, and Groff (38) substantiate their original claims that native urokinase is probably a single molecular species of 54,000, mol wt and suggest that White's S, fraction may have been subjected to artifactual proteolytic cleavage during purification.
The urokinase preparation used for immunization purposes in the present study was predominantly in the high molecular weight (54,000, mol wt) form, and the antiserum neutralized, on a biochemical activity basis, equal quantities of both the purified urokinase preparation used as antigen and native urokinase in human urine. This antiserum permits the detection of urokinase in biological fluids.
Antiserum specificity for human urokinase was established by demonstrating (a) lack of reactivity against the biochemical action of nonhuman and nonprimate plasminogen activators, including streptokinase, staphylokinase, and animal urines, tissue kinases, and supernates from animal cell culture lines and (b) lack of reactivity against human plasminogen activator extracted from adrenal glands and human milk activator. These experiments demonstrate immunologic dissimilarity between human urokinase and mammalian (nonprimate) urokinases. The plasminogen activator in rhesus monkey urine, baboon urine, and in unpurified and partially purified (cytokinase) supernates from rhesus monkey kidney cell tissue culture could be completely inhibited by urokinase antiserum. However, antiserum inhibitory titer against these activators was less than that against human urokinase, indicating partial cross-reactivity against these materials. These findings indicate partial immunologic identity and suggest a common phylogenetic derivation of the urokinase molecule in the two primates and in man. The similar inhibitory titers (37-50 %) against rhesus urine and supernate activator material from rhesus renal cell culture suggest that urokinase is produced in vitro by these cell lines. In the parallel situation with human material, identical inhibition was produced by urokinase antiserum against human urine, purified human urokinase, and supernate from human kidney cell culture (98-100 %), a finding which suggests that the latter cell lines produce human urokinase in vitro.
It is generally accepted that inhibition of enzymes by their antibodies involves steric hindrance to the access to the catalytic site (39, 40) , and frequently the kinetics of the inhibition are those of competitive inhibition, as in our studies. The steric hindrance hypothesis would provide an explanation for the strong inhibition seen with high molecular weight substrate (plasminogen), with no inhibition when the complex was tested on low molecular weight substrate (amino acid ester). Other explanations which might be invoked are (a) the difference of molar concentration of the respective substrates or (b) the difference in Km between the respective enzyme substrate reactions. However, in view of certain recent studies by Shapira and Arnon (41) on the mechanism of inhibition of papain by its specific antibodies, studies in which they too described inhibition of enzymatic action when large molecular weight substrate (casein), but not when low molecular weight substrate (amino acid ester) was used, steric hindrance would seem the most likely explanation for our findings.
Whether or not the urokinase antibodies prepared for this study were wholly of the precipitating variety remains uncertain, but at least on Ouchterlony plates a precipitin line, which was almost certainly attributable to urokinase precipitation, was seen. Shapira and Arnon also indicate that aggregation state of antigen-antibody complexes is of only minor importance with regard to complex biologic activity. The chief purpose of these studies was to deter-mine whether urokinase could be definitely identified in the plasma of man, and if so to determine the extent to which this specific enzymatic moiety, urokinase, contributed to total plasma activator activity. However, all attempts to demonstrate the presence of urokinase in human plasma were unsuccessful, although for technical reasons studies were performed in patients exhibiting enhanced rather than resting levels of plasminogen activator. Our data were obtained in normal volunteers in which enhanced levels of plasma plasminogen activator were induced by exercise, nicotinic acid administration, and therapeutic electroshock; in some subjects undergoing anesthesia, surgery, or inferior vena cava catheterization, high levels of plasma activator occurred spontaneously, and stimuli were not employed.
Assay accuracy was confirmed by the use of two methods, the 125I clot lysis assay and the euglobulin lysis time, which gave concordant results. Assay specificity was assured through the demonstration, first, that the antiserum did not inhibit plasmin and second, by the use of control studies in which 0.01 M EACA (an inhibitor of plasminogen activation) was added to the plasma samples. EACA treatment of subject plasma samples or urokinase-enriched plasma reduced activity to below 0.1 U in the euglobulin assay and to 0-14 % of initial activity with the 125I-labeled clot assay.
The peripheral venous samples, tested by the euglobulin clot lysis method, were wholly negative for the presence of urokinase and the results of additional studies with the 125I technique on these samples were similarly interpreted. However, as shown in Fig. 9 , anomalous but not statistically significant discrepancies were observed with high antiserum and control serum concentrations used in the 125I-labeled clot lysis experiment. Though these anomalous results were almost certainly due to technical artifact (see Table II in which discrepancies were absent), the 1251 technique experiments were insufficient to rigorously exclude the presence of trace amounts of urokinase in plasma.
However, both sets of experiments together would indicate the absence of urokinase from the plasma samples.
Additional studies were performed using blood drawn centrally from the distal inferior vena cava below the renal veins and from the renal veins, the latter site being the one at which urokinase concentration, if present, would presumably be the highest. The results, (Table III) with both 125IJ labeled clot and euglobulin lysis methods, demonstrate that in none of the six subjects was urokinase detected in renal vein or inferior vena cava plasma. It was also noted that fibrinolytic levels of plasma drawn from renal veins were not significantly different from those in the inferior vena cava, with the single exception of assays from the left renal vein of subject 1 in which elevated values were believed to result from the vasoactive effects of contrast media injected into the vessel immediately before sampling.
Furthermore, since it is known that the 50%o plasma clearance rate of plasminogen activator averages 13 + 5 min (37), it would be expected, were the kidney the principal site of activator production, that the activities between the distal IVC and renal vein samples would differ. However consistent differences between the fibrinolytic activity of the IVC and renal venous samples were not observed.
Our findings indicate that urokinase is immunologically distinct from human plasma activator, and that urokinase could not be detected in peripheral or renal venous plasma. Urokinase is also immunologically distinct from human milk activator and the tissue activator extracted from human adrenal glands. It is inferred that plasma activator is probably derived from tissue activator, especially that found in relation to blood vessels (42) (43) (44) .
